Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8017634 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP3A4CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL10060243 | 0.86 | CYP19A1 (0.46) | CYP19A1SMN1; SMN2CYP3A4CYP17A1CYP11B1 | |
| SCHEMBL4857317 | 0.82 | L3MBTL1 (0.39) | SMN1; SMN2CYP3A4CYP17A1TSHRSLC6A2 | |
| SCHEMBL7089958 | 0.80 | KCNA5 (0.46) | CYP19A1SMN1; SMN2KDM4EGAAIDO1 | |
| SCHEMBL2907043 | 0.77 | CYP19A1 (0.68) | CYP19A1CYP3A4CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL8545947 | 0.75 | HPGD (0.37) | CYP19A1SMN1; SMN2CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL8327525 | 0.75 | GAA (0.34) | SMN1; SMN2CYP3A4CYP11B2SLC6A2SLC6A4 | |
| SCHEMBL21340486 | 0.75 | MAPT (0.52) | SLC6A2SLC6A3HIF1ACYP2C19LMNA | |
| SCHEMBL14033471 | 0.74 | LMNA (0.47) | CYP19A1SMN1; SMN2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23489766 | 0.73 | GAA (0.39) | SMN1; SMN2CYP3A4CYP11B2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107150-A1 | New Compounds II | PROXIMAGEN LTD (GB) | 2014-04-17 | — | — | US | disclosed |
| US-8633318-B2 | Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder | PROXIMAGEN LTD (GB) | 2014-01-21 | — | — | US | disclosed |
| EP-2328895-B1 | Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2328895-A1 | NEW COMPOUNDS II | Proximagen Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010031791-A1 | NEW COMPOUNDS II | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195992-A1 | NEW COMPOUNDS II | SSB, NFKBIA, ALOX15B | CYP19A1 419/4885SMN1; SMN2 1083/4885CYP3A4 140/4885 |
| US-20140107150-A1 | New Compounds II | SSB, NFKBIA, ALOX15B | CYP19A1 419/4885SMN1; SMN2 1083/4885CYP3A4 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.